Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | XBP1 | P17861 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6707221 | 0.83 | ALDH1A1 (0.47) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL12132675 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL28343034 | 0.80 | PRKCA (0.63) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL10414853 | 0.79 | PRKCA (0.57) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL1073543 | 0.79 | LMNA (0.59) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL6895298 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL12851852 | 0.79 | ALDH1A1 (0.54) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL7797331 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL5485543 | 0.78 | ALDH1A1 (0.46) | ALDH1A1MAPTKMT2ANPSR1MEN1 | |
| SCHEMBL12972101 | 0.78 | PRKCA (0.56) | ALDH1A1MAPTKMT2ANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5491167-A | INHIBITORS OF CHOLESTEROL BIOSYNTHESIS | SANKYO COMPANY, LIMITED (JP) | 1996-02-13 | — | — | US | claimed |
| US-11720019-B2 | Resist composition and pattern forming process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-20210278763-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-09 | — | — | US | disclosed |
| US-8933251-B2 | Fluorinated monomer of cyclic acetal structure, polymer, resist protective coating composition, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20130231491-A1 | FLUORINATED MONOMER OF CYCLIC ACETAL STRUCTURE, POLYMER, RESIST PROTECTIVE COATING COMPOSITION, RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-09-05 | — | — | US | disclosed |
| US-8431323-B2 | Fluorinated monomer of cyclic acetal structure, polymer, resist protective coating composition, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | HUNTER-FLEMING LIMITED (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-1848426-B1 | TRICYCLIC CYTOPROTECTIVE COMPOUNDS | HUNTER FLEMING LTD (GB) | 2012-08-01 | — | — | EP | disclosed |
| EP-2097079-B1 | MODULATION OF PROSTAGLANDIN/CYCLOOXYGENASE METABOLIC PATHWAYS | HUNTER FLEMING LTD (GB) | 2012-06-27 | — | — | EP | disclosed |
| US-20110305979-A1 | RESIST TOP COAT COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-0570245-A2 | Octahydronaphthalene oxime derivatives for cholesterol biosynthesis inhibition, their preparation and use | SANKYO COMPANY LIMITED (JP) | 1993-11-18 | — | — | EP | disclosed |
| EP-0560613-A1 | Antimicrobial carbapenem derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1993-09-15 | — | — | EP | disclosed |
| US-5242914-A | 2-(heterocyclylthio) carbapenem derivatives, their preparation and their use as antibiotics | SANKYO COMPANY, LIMITED (JP) | 1993-09-07 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0518558-A1 | 1-Methylcarbapenem derivatives, their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1992-12-16 | — | — | EP | disclosed |
| US-5104867-A | 2-(HETEROCYCLYLTHIO)CARBAPENEM DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIBIOTICS | SANKYO COMPANY, LIMITED (JP) | 1992-04-14 | — | — | US | disclosed |
| EP-0443883-A1 | Carbapenem derivatives having antibiotic activity, their preparation and their use | Sankyo Company Limited (JP) | 1991-08-28 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
| EP-0363223-A2 | 3-Aryloxymethyl-cephalosporin derivatives, their preparation and their medical use | Sankyo Company Limited (JP) | 1990-04-11 | — | — | EP | disclosed |
| EP-0337637-A1 | 2-(Heterocyclylthio)carbapenem derivatives their preparation and their use as antibiotics | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11720019-B2 | Resist composition and pattern forming process | SLC11A2, ABCC1, SFPQ | ALDH1A1 2679/4885MAPT 3820/4885KMT2A 2458/4885 |
| US-20210278763-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SLC11A2, ABCC1, SFPQ | ALDH1A1 2679/4885MAPT 3820/4885KMT2A 2458/4885 |
| US-20130023504-A1 | Modulation of Prostaglandin/Cyclooxygenase Metabolic Pathways | PTGES2, PTGES, PTGS2 | ALDH1A1 804/4885MAPT 4690/4885KMT2A 3544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.